Generation Bio Inc. (GBIO) News
Filter GBIO News Items
GBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GBIO News Highlights
- For GBIO, its 30 day story count is now at 2.
- Over the past 1 day, the trend for GBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and NOTE are the most mentioned tickers in articles about GBIO.
Latest GBIO News From Around the Web
Below are the latest news stories about GENERATION BIO CO that investors may wish to consider to help them evaluate GBIO as an investment opportunity.
Charles Rowland Bought 179% More Shares In Generation BioPotential Generation Bio Co. ( NASDAQ:GBIO ) shareholders may wish to note that the Independent Director, Charles... |
Director Rowland Charles A Jr Acquires 342,960 Shares of Generation Bio Co (GBIO)In a notable insider transaction, Rowland Charles A Jr, a director at Generation Bio Co, has significantly increased his stake in the company. |
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA PlatformsCompany to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge |
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N |
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP PlatformFigure 1 mRNA expression with T cell ctLNP in humanized mouse model Figure 2 Dose response with T cell ctLNP in humanized mouse model Figure 3a Half-life of stealth LNP in NHPs and mice Figure 3b Biodistribution of stealth LNP in NHPs 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolon |
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNANHP IL-6 profile NHP IL-6 levels following IV infusion of mRNA, ceDNA, or iqDNA delivered via LNP at 1 mg/kg – Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA – Company is advancing iqDNA in lieu of prior ceDNA constructs across all programs, including its lead program in hemophilia A – Company is extending cash runway gu |
Generation Bio to Present at the Jefferies Cell & Genetic Medicine SummitCAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Tuesday, September 26, 2023 at 9:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the com |
We're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Insider Buyers Lose US$80k As Generation Bio Sheds US$37mThe recent 11% drop in Generation Bio Co.'s ( NASDAQ:GBIO ) stock could come as a blow to insiders who purchased... |
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth ConferenceCAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord Healthcare Conference on Thursday, August 10, 2023 at 11:00 a.m. ET in Boston. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. |